Results 211 to 220 of about 248,214 (310)

Metabolic fate of drugs of abuse and new psychoactive substances: A pilot study on a novel workflow using a zebrafish embryo model combined with human microdosing

British Journal of Clinical Pharmacology, EarlyView.
Aim The aim of this study was to develop a novel workflow to identify human urine biomarkers for drugs of abuse and new psychoactive substances. Metabolites of amphetamine, cocaine, LSD, MDMA, methamphetamine, THC, MDMB‐CHMICA, and MDPPP were first identified in a zebrafish embryo (ZE) metabolism study followed by comparison to most abundant human ...
Simon K. Wellenberg, Tanja M. Gampfer, Lea Wagmann, Philip Schippers, Jennifer Herrmann, Rolf Müller, Folker Westphal, Markus R. Meyer   +7 more
wiley   +1 more source

Prescribing Practices, Motivations, and Behaviors Contributing to Prescription Stimulant Misuse Among Medical Students at an Allopathic Medical School: Cross-Sectional Survey Study. [PDF]

Cureus
Short HB, Lehman E, Nelluri S, Latronica J, Bali B.   +4 more
europepmc   +1 more source

Clinical Images: Skeletal fluorosis presenting with diffuse periostitis and polyarticular synovitis

Arthritis &Rheumatology, EarlyView.
Mitali Sen
wiley   +1 more source

Mental health symptoms among men and women Australian professional football (soccer) players: a survey-based cross-sectional study. [PDF]

BMC Sports Sci Med Rehabil
Mifsud D, van Rensburg DCJ, Busch B, Mankowska R, Taylor B, Kerkhoffs G, Gouttebarge V.   +6 more
europepmc   +1 more source

We ought to discuss the social construction of cadavers: Here's why and how

Anatomical Sciences Education, EarlyView.
Fatima Ehsan, Susan Lamb
wiley   +1 more source

A scoping review of thresholds for responder and time‐to‐event analysis of patient‐reported outcomes in breast cancer trials

British Journal of Clinical Pharmacology, EarlyView.
Patient‐reported outcomes (PROs) are essential for assessing clinical benefit and tolerability from the patient's perspective. In oncology trials, PRO data analysis often involves responder and time‐to‐event analyses, which depend on predefined thresholds to determine clinically meaningful change.
Anna Margarete Maria Thurner, Daniela Krepper, Micha Johannes Pilz, Lisa Marie Storz, Maike Thumfart, Johannes Maria Giesinger   +5 more
wiley   +1 more source

Risk Modeling and Association Pathways Integrating Psychosocial Factors for Drug Misuse in Adolescents and Young Adults: A Machine Learning Approach.

Eur Addict Res
Li Z, Li N, He Y, Zhang T, Peng A, Jiang Z, Wen C, Wu Z, Chung OKJ, Li WHC, Cheng Y, Xia W.   +11 more
europepmc   +1 more source

The role of positive parental involvement in preventing drug and substance misuse among young people in Zimbabwe: a qualitative study. [PDF]

BMJ Open
Kusemwa C, Kabonga I, Mazuruse I, Musara E.   +3 more
europepmc   +1 more source

Zuranolone: A case study in (regulatory) rush to judgement?

British Journal of Clinical Pharmacology, EarlyView.
Abstract Sage, in collaboration with Biogen, submitted a new drug approval for zuranolone for postpartum depression (PPD) and major depressive disorder (MDD) in December 2022. In August 2023, the US Food and Drug Administration granted approval for PPD but denied approval for MDD.
Lisa Cosgrove, Milutin Kostic, Barbara Mintzes, Gianna D'Ambrozio, Allen Shaughnessy   +4 more
wiley   +1 more source